(lp0
S'The Long Case For Lexicon Pharmaceuticals Seeking Alpha - Feb 16, 2017 Lexicon Pharmaceuticals  is about to become a commercial stage company. The PDUFA date for telotristat ethyl  is on February 28, with a high likelihood of approval.'
p1
aS'2 Key Events On The Horizon For Lexicon Pharmaceuticals Seeking Alpha - Jan 26, 2017 Lexicon Pharmaceuticals is a small biopharmaceutical company with clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications.'
p2
aS"FDA OKs Lexicon Pharma's telotristat etiprate for carcinoid syndrome Seeking Alpha - Feb 28, 2017 The FDA approves Lexicon Pharmaceuticals'  XERMELO  250 mg for the treatment of carcinoid syndrome diarrhea, in combination with somatostatin therapy  in adult patients inadequately controlled with SSA therapy.FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug - ReutersFDA Approves Lexicon Drug XERMELO  250 mg As First And ... - PR Newswire "
p3
aS'Stock in Review: Lexicon Pharmaceuticals, Inc.  Rives Journal - 9 hours ago Lexicon Pharmaceuticals, Inc.  currently has a Gross Margin  ratio of -0.199346. Robert Novy-Marx has provided investors with insights on finding high-quality value stocks.'
p4
aS'Earnings Reaction History: Lexicon Pharmaceuticals Inc., 33.3% Follow-Through ... Nasdaq - Mar 3, 2017 Lexicon Pharmaceuticals Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session.'
p5
aS'Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 ... PR Newswire  - Mar 3, 2017 THE WOODLANDS, Texas, March 3, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. , today reported financial results for the three months and year ended December 31, 2016 and provided an overview of key milestones for the&nbsp;...Lexicon Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 02 - Equities.comLexicon Pharmaceuticals, Inc.  Issues Quarterly Earnings Results, Beats ... - Chaffey Breeze'
p6
aS'Lexicon Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 27 Equities.com - Feb 27, 2017 Lexicon Pharmaceuticals Inc.  traded on unusually high volume on Feb. 27, as the stock gained 4.64% to close at $16.45.Lexicon Pharmaceuticals  Stock: FDA Approves XERMELO - CNA Finance The Lexicon Pharmaceuticals, Inc.  Upgraded by Zacks Investment Research ... - DailyQuint'
p7
aS'Lexicon To Present At The Barclays Global Healthcare Conference PR Newswire  - Mar 9, 2017 Lexicon Pharmaceuticals, Inc.  announced today that Lexicon management will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 3:50 p.m.'
p8
aS'Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference PR Newswire  - Mar 6, 2017 THE WOODLANDS, Texas, March 6, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.  announced today that Lexicon management will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, March 8,&nbsp;...'
p9
aS'Estimating the intrinsic value of Lexicon Pharmaceuticals Inc  Simply Wall St - Mar 3, 2017 How far off is Lexicon Pharmaceuticals  to its intrinsic value? I am going to take a look now using a method called discounted cash flow or DCF.'
p10
a.